Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• DMRA reported a quarterly loss of $0.39 per share, beating analysts’ consensus estimate of a $0.45 loss by $0.06.
• Shares fell 1.3% to $29.54 during Monday trading, while the company’s market capitalization stood at approximately $1.82 billion.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $44 price target; institutional investors own 14.2% of the stock.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.06, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Down 1.3%

Shares of DMRA traded down $0.38 during mid-day trading on Monday, reaching $29.54. The company had a trading volume of 216,183 shares, compared to its average volume of 388,455. The stock has a market capitalization of $1.82 billion, a P/E ratio of -5.29 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The stock has a 50 day moving average of $26.46 and a two-hundred day moving average of $26.28.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds have recently bought and sold shares of the stock. Ikarian Capital LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $6,574,000. Jain Global LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,774,000. Remedium Capital Partners LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,772,000. Boothbay Fund Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,204,000. Finally, Connective Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $100,000. Hedge funds and other institutional investors own 14.20% of the company's stock.

Wall Street Analysts Forecast Growth

DMRA has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an "outperform" rating and a $40.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Wedbush increased their price target on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, July 30th. Finally, TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They set a "buy" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source